



(11) **EP 1 708 726 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
15.10.2008 Bulletin 2008/42

(51) Int Cl.:
A61K 36/82 (2006.01)

(21) Application number: **05700833.6**

(86) International application number:
PCT/EP2005/000206

(22) Date of filing: **12.01.2005**

(87) International publication number:
WO 2005/067952 (28.07.2005 Gazette 2005/30)

(54) **FORMULATION FOR TREATING OBESITY AND ASSOCIATED METABOLIC SYNDROME**

FORMULIERUNG ZUR BEHANDLUNG VON FETTLLEIBIGKEIT UND ASSOZIIERTEM
STOFFWECHSELSYNDROM

FORMULATION DESTINEE AU TRAITEMENT DE L'OBESEITE ET DU SYNDROME METABOLIQUE
ASSOCIE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR**

(56) References cited:
**FR-A- 2 712 191 US-A- 4 598 089
US-A- 5 804 596**

(30) Priority: **15.01.2004 PL 36441104**

(43) Date of publication of application:
11.10.2006 Bulletin 2006/41

(73) Proprietor: **Scandinavian Clinical Nutrition I
Sverige AB
114 56 Stockholm (SE)**

(72) Inventor: **KROTKIEWSKI, Marcin
S-436 39 Askim (SE)**

(74) Representative: **Örtenblad, Bertil Tore et al
Noréns Patentbyrå AB
P.O. Box 10198
100 55 Stockholm (SE)**

- **DULLOO A G ET AL: "Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans" AMERICAN JOURNAL OF CLINICAL NUTRITION, BETHESDA, MD, US, vol. 70, no. 6, December 1999 (1999-12), pages 1040-1045, XP001154724 ISSN: 0002-9165 cited in the application**
- **ANONYMOUS: "Les suppléments nutritionnels de la minceur"[Online] 1 May 2004 (2004-05-01), page 1-5, XP002330877 Retrieved from the Internet: URL: <http://www.nutranews.org/fra/index.php?articleid=4024> [retrieved on 2005-06-07]**
- **ANONYMOUS: "Fat burners overview"[Online] page 1-8, XP002330878 Retrieved from the Internet: URL: <http://www.realsolutionsmag.com/fat-burners/fat-burners.html> [retrieved on 2005-06-07]**
- **ANONYMOUS: "Evoplex TM"[Online] page 1-5, XP002330879 Retrieved from the Internet: URL: <http://www.befit.ca/evoplex.html> [retrieved on 2005-06-07]**
- **ANONYMOUS: "FatBlaster MAX"[Online] page 1-2, XP002330880 Retrieved from the Internet: URL: <http://www.discountnaturalhealth.com/product1540.htm> [retrieved on 2005-06-07]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 708 726 B1

[0040] After 14 weeks, body weight decrease was equal 6.06 % in the control group and 9,28 % in the treated group which was receiving the formulation of the invention (fig. 5). Those values expressed in kilograms are equal to 5.54 kg and 8.51 kg respectively. Difference between these two groups was 53.6 %. Differences were found statistically significant.

[0041] Decrease of body fat concentration was equal to -4.0 kg in the control group and -6.6 kg in the treated group (fig 6). Simultaneously, decrease of LDL plasma cholesterol concentration by 1.58 mg/dl in the control group and by 6.08 mg/dl in the treated group (fig.7) and total plasma cholesterol by 3.92 mg/dl and 19.42 mg/dl (fig.8) respectively was observed. Reduction of cholesterol concentration was accompanied by decrease of plasma triglyceride concentration by 6.63 mg/dl in the treated group, while in the control group triglyceride concentration increased by 1.42 mg/dl (fig.9).

[0042] The quoted studies have verified

a) Formulation of the invention is accelerating weight loss during dietary treatment of obesity.

b) Formulation of the invention contains active components which effects are synergistically strengthening each other, so that effect of their mixture is significantly greater than the effect of any separate component alone.

Claims

1. Formulation for treating obesity and associated metabolic syndrome, comprising a combination of vegetable extracts, characterized in that it consists of:

- a) 20-90% wt. of Green tea extract, containing more than 70 % of catechines, preferably containing Epigallocatechin galate (EGCG),
- b) 2-30 % wt. of *Coleus forskohlii* extract, containing at least 10 % of diterpene forskolin,
- c) 5-58 % wt. of Yerba Maté extract, containing 2-4 % of caffeine and caffeoylquinic acids (CGA),
- d) 7.5-45 wt. of *Betula alba* extract containing at most 3% of flavonides.

2. Formulation according to claim 1, characterized in that it further comprises an effective amount of vegetable extract of white kidney beans (*Phaseolus Vulgaris*).

3. Formulation according to claim 1 or 2, characterized in that Green tea extract is an extract obtained by water and/or ethyl acetate and water extraction in low temperature under reduced pressure.

4. Formulation according to claim 1 or 2, characterized in that Green tea extract is an extract obtained by alcohol extraction or extraction conducted in the presence of fat solvents for example selected from a group consisting of: methanol-chloroform mixture, alcohol ethers and detergents, in low temperature under reduced pressure.

5. Formulation according to claim 3 or 4, characterized in that Green tea extract comprises at least 30 % of EGCG

6. Formulation according to claim 3 or 4, characterized in that Green tea extract comprises at least 50 % of EGCG

7. Formulation according to claim 3 or 4, characterized in that Green tea extract comprises at least 80 % of EGCG

8. Formulation according to any of the claims 1-7, characterized in that it further comprises non-active excipients or fillers selected from a group consisting of: silicon dioxide, magnesium stearate, laurylsulphate, other surfactants for example selected from a group consisting of: sodium carboxymethylcellulose, hydroxypropylmethyl cellulose and microcrystalline cellulose, anti-caking agents such as dicalcium phosphate; and materials forming the shell of the capsule.

9. Formulation for treating obesity and associated metabolic syndrome, comprising a combination of selected vegetable extracts, characterized in that it consists of:

- a) 20-80% wt. of Green tea extract, containing more than 70 % of catechines, preferably containing Epigallocatechin galate (EGCG),
- b) 2-30 % wt. of *Coleus forskohlii* extract, containing at least 10 % of diterpene forskolin.
- c) 5-50 % wt. of Guarana extract, containing more than 8 % of caffeine and caffeine-like polyphenoles (chlorogenic acids - CGA)
- d) 7.5-45 % wt. of *Betula alba* extract containing at most 3% of flavonides.

10. Formulation according to claim 9, **characterized in that** it further comprises an effective amount of vegetable extract of white kidney beans (*Phaseolus Vulgaris*).
- 5 11. Formulation according to claim 9 or 10, **characterized in that** Green tea extract is an extract obtained by water and/or ethyl acetate and water extraction in low temperature under reduced pressure.
12. Formulation according to claim 9 or 10, **characterized in that** Green tea extract is an extract obtained by alcohol extraction or extraction conducted in the presence of fat solvents for example selected from a group consisting of: methanol-chloroform mixture, alcohol ethers and detergents, in low temperature under reduced pressure.
- 10 13. Formulation according to claim 11 or 12, **characterized in that** Green tea extract comprises at least 30 % of EGCG
14. Formulation according to claim 11 or 12, **characterized in that** Green tea extract comprises at least 50 % of EGCG
- 15 15. Formulation according to claim 11 or 12, **characterized in that** Green tea extract comprises at least 80 % of EGCG
16. Formulation according to any of the claims 9-15, **characterized in that** it further comprises non-active excipients or fillers selected from a group consisting of silicon dioxide, magnesium stearate, laurylsulphate, other surfactants for example selected from a group consisting of: sodium carboxymethylcellulose, hydroxypropylmethyl cellulose and microcrystalline cellulose, anti-caking agents such as dicalcium phosphate; and materials forming the shell of the capsule.
- 20

Patentansprüche

- 25 1. Formulierung zur Behandlung von Fettleibigkeit und assoziiertem Stoffwechselsyndrom, mit einer Kombination von Gemüseextrakten, **dadurch gekennzeichnet, dass** sie besteht aus:
 - 30 a) 20 bis 90 Gewichtsprozent Extrakt von Grünem Tee, mit mehr als 70 % Katechinen, vorzugsweise enthalten Epicallocatehingallat (EGCG),
 - b) 2 - 30 Gewichtsprozent Extrakt von *Coleus Forskholii*, mit wenigstens 10 % Diterpenforskolin,
 - c) 5 - 58 Gewichtsprozent Extrakt von Yerba Mate, mit 2 - 4 % Koffein und Kaffeeoylquiniksäuren (CGA),
 - d) 7,5 - 45 Gewichtsprozent Extrakt von *Betula Alba*, mit höchstens 3 % Flavoniden.
- 35 2. Formulierung nach Anspruch 1, **dadurch gekennzeichnet, dass** sie außerdem eine wirksame Menge eines Gemüseextrakts von weißen Bohnen (*Phaseolus Vulgaris*) enthält.
3. Formulierung nach Anspruch 1 oder 2, **dadurch gekennzeichnet, dass** das Extrakt von Grünem Tee ein Extrakt ist, welches durch Wasser und/oder Ethylacetat und eine Wasserextraktion bei niedriger Temperatur unter vermindertem Druck erhalten wird.
- 40 4. Formulierung nach Anspruch 1 oder 2, **dadurch gekennzeichnet, dass** das Extrakt von Grünem Tee ein Extrakt ist, welches durch Alkoholextraktion oder durch eine Extraktion, welche in Gegenwart von Fettlösem durchgeführt wird, welche beispielsweise ausgewählt sind aus einer Gruppe, welche aus einer Methanol-Chloroform-Mischung, Alkoholethern und Detergentien besteht, bei niedriger Temperatur unter vermindertem Druck, erhalten wird.
- 45 5. Formulierung nach Anspruch 3 oder 4, **dadurch gekennzeichnet, dass** das Extrakt von Grünem Tee wenigstens 30 % EGCG enthält.
- 50 6. Formulierung nach Anspruch 3 oder 4, **dadurch gekennzeichnet, dass** das Extrakt von Grünem Tee wenigstens 50 % EGCG enthält.
7. Formulierung nach Anspruch 3 oder 4, **dadurch gekennzeichnet, dass** das Extrakt von Grünem Tee wenigstens 80 % EGCG enthält.
- 55 8. Formulierung nach einem der Ansprüche 1 bis 7, **dadurch, dass** sie außerdem nicht aktive Exciipienten oder Füllstoffe aufweist, welche aus einer Gruppe ausgewählt sind, welche besteht aus: Silikondioxid, Magnesiumstearat, Laurylsulphat, anderen oberflächenaktiven Stoffen, beispielsweise ausgewählt aus einer Gruppe, welche besteht aus: